OpRegen

AssetCell therapyAlso RG6501

Allogeneic stem cell-derived retinal pigment epithelial cell replacement therapy

Stage
Phase 2
Modality
Cell therapy
Target
Stem cell maintenance
Indications
1
Trials
1
Developers
1

Indications

1
  • Targets and what it contains1
  • Owner and partners1
  • Trials1
  • Evidence for its targets1
  • Competitors1
  • Aging relevance1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Updated 7 Oct 2026 · 2 sources

Assets